Search

Author/Creator Killing, Birgitta

1. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. (September 2018)

Authors:
Hegewisch-Becker, Susanna; Nöpel-Dünnebacke, Stefanie; Hinke, Axel; Graeven, Ullrich; Reinacher-Schick, Anke; Hertel, Jan; Lerchenmüller, Christian A.; Killing, Birgitta; Depenbusch, Reinhard; Al-Batran, Salah-Eddin; Lange, Thoralf; Dietrich, Georg; Tannapfel, Andrea; Arnold, Dirk
Journal:
European journal of cancer
Issue:
Volume 101(2018)
Page Start:
105
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Issue 13 (October 2015)

Authors:
Hegewisch-Becker, Susanna; Graeven, Ullrich; Lerchenmüller, Christian A; Killing, Birgitta; Depenbusch, Reinhard; Steffens, Claus-Christoph; Al-Batran, Salah-Eddin; Lange, Thoralf; Dietrich, Georg; Stoehlmacher, Jan; Tannapfel, Andrea; Reinacher-Schick, Anke; Quidde, Julia; Trarbach, Tanja; Hinke...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 13(2015)
Page Start:
1355
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search